Lenalidomide in combination with dexamethasone as first-line therapy in transplant-ineligible patients with Multiple Myeloma: Interim Results of the observational study FIRST-NIS. 29. Juli 2019 H. Nückel; H.-J. Hurtz; H. Schulz; M. Schulze; M. Koenigsmann; T. Dechow; M. Merling; L. Houet; C. Vannier; K. Potthoff; 2019. HemaSphere. 3():263–264, JUN 2019 DOI: 10.1097/01.HS9.0000560764.61601.55 Issn Print: 2572-9241 Abstract Pertuzumab beim HER2-positiven metastasierten Mammakarzinom in der Routinebehandlung – Daten aus dem Tumorregister Mammakarzinom. Overkamp, F; Frühauf, S; Fietz, T; Behringer, J; Kruggel, L; Wetzel, N; Marschner, N, 2019. Senologie 2019; 16(02): 31 – 31 DOI: 10.1055/s-0039-1688031… Weiterlesen Twice weekly carfilzomib is an accepted treatment by patients with Multiple Myeloma who have received at least one prior therapy: Interim results if the CARO study. W. Knauf; A. Ammon; J. Uhlig; M. Merling; H.-J. Hurtz; T. Riedt; H. Schulz; C. Vannier; N. Marschner; K. Potthoff; 2019. HemaSphere. 3():646–647, JUN… Weiterlesen